ClinicalTrials.gg
CompletedNCT00321711Updated Oct 17, 2018Results posted

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

A Phase 2 interventional study of Placebo and AMG 531 (Romiplostim) in MDS, Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.

Enrollment
7th of 11
69 · median 72
Started
2006
with 2 others
Phase 2
5 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 7th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 3rd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Myelodysplastic Syndromes by Amgen as a file.
02

Study summary

The purpose of this study is to evaluate the effect of Romiplostim (AMG 531) on the incidence of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet transfusions) in subjects with low or intermediate risk Myelodysplastic Syndrome (MDS) receiving hypomethylating agents. It is hypothesized that Romiplostim administration, at the appropriate dose and schedule, will result in reduction in the incidence of clinically significant thrombocytopenic events in low or intermediate risk MDS subjects receiving hypomethylating agents.

03

Conditions studied

  • MDS
  • Myelodysplastic Syndromes
  • Thrombocytopenia

Keywords

  • MDS
  • Myelodysplastic Syndromes
  • Refractory Cytopenias
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Diagnosis of MDS by bone marrow based on the World Health Organization (WHO) classification - Low, Intermediate-1 or Intermediate-2 risk category MDS using the IPSS (International Prognostic Scoring System) - Planned to receive either azacytidine 75 mg/m2 by subcutaneous administration each day for 7 days or decitabine 20 mg/m2 by intravenous administration each day for 5 days for at least 4 cycles Exclusion Criteria:

  • Prior exposure to >3 cycles hypomethylating agents
  • Prior history of leukemia or aplastic anemia
  • Prior history of bone marrow transplantation
  • Prior (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ³ 3 years before randomization
  • Active or uncontrolled infections
  • Unstable angina, congestive heart failure [ (New York Heart Association) > class II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
  • History of arterial thrombosis ( eg, stroke or ) in the past year
  • History of venous thrombosis that currently requires anti-coagulation therapy
  • Received IL-11 within 4 weeks of screening
  • Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication
  • Have previously received any other thrombopoietic growth factor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    Dose level 1 500 AMG 531 (Part A - azacitidine)

    500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles

    Biological: AMG 531 (Romiplostim) · Drug: Azacitidine

  • Active comparator
    Dose level 1 750 AMG 531 (Part B - decitabine)

    750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles

    Biological: AMG 531 (Romiplostim) · Drug: Decitabine

  • Active comparator
    Dose level 2 750 AMG 531 (Part A - azacitidine)

    750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles

    Biological: AMG 531 (Romiplostim) · Drug: Azacitidine

  • Placebo comparator
    Placebo (Part A - azacitidine)

    Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles

    Drug: Placebo · Drug: Azacitidine

  • Placebo comparator
    Placebo (Part B - decitabine)

    Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles

    Drug: Placebo · Drug: Decitabine

Interventions

  • DrugPlacebo

    Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.

  • AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.

  • hypomethylating agent

  • hypomethylating agent

06

What researchers measure

Primary outcomes

  1. Occurrence of a Clinically Significant Thrombocytopenic Event

    Occurrence of a clinically significant thrombocytopenic event within the participant, defined as any platelet count obtained from day 15 of cycle 1 through the end of the interim follow-up visit that was less than 50 x 10\^9/L or receipt of platelet transfusions at any time through the interim follow-up visit.

    Time frame: Treatment period (up to 20 weeks)

Secondary outcomes

  1. Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia

    Occurrence of hypomethylating agent dose reduction and delay due to thrombocytopenia

    Time frame: Treatment period (up to 20 weeks)

  2. Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period

    CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.

    Time frame: Treatment period (up to 20 weeks)

  3. Platelet Transfusion

    Occurrence of one or more platelet transfusions from study day 1 through the interim follow-up visit (16 weeks)

    Time frame: Study day 1 through the interim follow-up visit (up to 20 weeks)

07

Results

Posted Apr 5, 2011

Participant flow

Participants in Part A were enrolled from 9 November 2006 through 31 August 2007; participants in Part B were enrolled from 26 March 2008 through 3 November 2008. Participants who enrolled in Part A were not eligible for enrollment in Part B.

Part A
Participant flow — Part A
MilestoneRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Started13131400
Completed83300
Not completed5101100
Withdrew: Adverse event33200
Withdrew: Withdrawal by subject11100
Withdrew: Disease progression01000
Withdrew: Requirement for alternative therapy02100
Withdrew: Physician decision01300
Withdrew: Other12300
Withdrew: Protocol deviation00100
Part B
Participant flow — Part B
MilestoneRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Started0001415
Completed000810
Not completed00065
Withdrew: Noncompliance00001
Withdrew: Adverse event00021
Withdrew: Disease progression00010
Withdrew: Physician decision00012
Withdrew: Death00021

Outcome measures

PrimaryOccurrence of a Clinically Significant Thrombocytopenic Event

Occurrence of a clinically significant thrombocytopenic event within the participant, defined as any platelet count obtained from day 15 of cycle 1 through the end of the interim follow-up visit that was less than 50 x 10\^9/L or receipt of platelet transfusions at any time through the interim follow-up visit.

Time frame:
Treatment period (up to 20 weeks)
Reported as:
Number · Participants
Occurrence of a Clinically Significant Thrombocytopenic Event
ParticipantsRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Occurrence of a Clinically Significant Thrombocytopenic Event118101112
Statistical analysis
  • Romiplostim (AMG 531) Placebo Plus Decitabine vs Romiplostim (AMG 531) 750 mcg Plus Decitabine · Odds ratio (or): 1.032 · 95% CI 0.153 to 6.950
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 750 mcg Plus Azacitidine · Odds ratio (or): 0.333 · 95% CI 0.028 to 3.926
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 500 mcg Plus Azacitidine · Odds ratio (or): 0.118 · 95% CI 0.007 to 1.882Adjusted by the stratification factor
SecondaryHypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia

Occurrence of hypomethylating agent dose reduction and delay due to thrombocytopenia

Time frame:
Treatment period (up to 20 weeks)
Reported as:
Number · Participants
Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia
ParticipantsRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia11000
Statistical analysis
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 500 mcg Plus Azacitidine · Odds ratio (or): 1.000 · 95% CI 0.063 to 15.988Romiplostim/placebo
SecondaryAchieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period

CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.

Time frame:
Treatment period (up to 20 weeks)
Reported as:
Number · Participants
Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period
ParticipantsRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period21135
Statistical analysis
  • Romiplostim (AMG 531) Placebo Plus Decitabine vs Romiplostim (AMG 531) 750 mcg Plus Decitabine · Odds ratio (or): 1.827 · 95% CI 0.347 to 9.618Romiplostim/placebo
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 750 mcg Plus Azacitidine · Odds ratio (or): 0.445 · 95% CI 0.037 to 5.325Romiplostim/placebo
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 500 mcg Plus Azacitidine · Odds ratio (or): 0.444 · 95% CI 0.032 to 6.080Romiplostim/placebo
SecondaryPlatelet Transfusion

Occurrence of one or more platelet transfusions from study day 1 through the interim follow-up visit (16 weeks)

Time frame:
Study day 1 through the interim follow-up visit (up to 20 weeks)
Reported as:
Number · Participants
Platelet Transfusion
ParticipantsRomiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus Decitabine
Platelet Transfusion96587
Statistical analysis
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 750 mcg Plus Azacitidine · Difference in incidence rate: -33.5 · 95% CI -69.0 to 2.0Romiplostim - placebo
  • Romiplostim (AMG 531) Placebo Plus Decitabine vs Romiplostim (AMG 531) 750 mcg Plus Decitabine · Odds ratio (or): 0.315 · 95% CI 0.029 to 3.412
  • Romiplostim (AMG 531) Placebo Plus Azacitidine vs Romiplostim (AMG 531) 500 mcg Plus Azacitidine · Odds ratio (or): 0.211 · 95% CI 0.021 to 2.082

Adverse events

Collected over Up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Placebo—9/13 (69.2%)11/13 (84.6%)
Part A Romiplostim 500 µg—4/13 (30.8%)13/13 (100%)
Part A Romiplostim 750 µg—10/14 (71.4%)14/14 (100%)
Part B Placebo—8/14 (57.1%)14/14 (100%)
Part B Romiplostim 750 µg—8/15 (53.3%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPart A PlaceboPart A Romiplostim 500 µgPart A Romiplostim 750 µgPart B PlaceboPart B Romiplostim 750 µg
Febrile neutropeniaBlood and lymphatic system disorders3/131/131/143/144/15
PyrexiaGeneral disorders2/130/131/140/142/15
AnaemiaBlood and lymphatic system disorders1/130/132/140/140/15
PneumoniaInfections and infestations1/130/132/142/142/15
HypotensionVascular disorders0/130/132/140/140/15
Urinary tract infectionInfections and infestations0/130/130/140/142/15
PancytopeniaBlood and lymphatic system disorders1/130/130/140/140/15
Atrial fibrillationCardiac disorders0/131/131/140/140/15
Atrial flutterCardiac disorders0/131/130/140/140/15
Sick sinus syndromeCardiac disorders0/131/131/140/140/15
Most frequent other events
Showing 10 of 253
Most frequent other events
EventPart A PlaceboPart A Romiplostim 500 µgPart A Romiplostim 750 µgPart B PlaceboPart B Romiplostim 750 µg
NeutropeniaBlood and lymphatic system disorders4/134/132/149/144/15
ConstipationGastrointestinal disorders5/137/137/145/144/15
NauseaGastrointestinal disorders6/134/136/146/145/15
DiarrhoeaGastrointestinal disorders1/134/136/145/143/15
FatigueGeneral disorders5/134/132/143/142/15
DyspnoeaRespiratory, thoracic and mediastinal disorders5/134/131/141/144/15
EpistaxisRespiratory, thoracic and mediastinal disorders5/133/131/143/143/15
Decreased appetiteMetabolism and nutrition disorders0/133/135/142/142/15
Pain in extremityMusculoskeletal and connective tissue disorders1/132/135/141/143/15
ThrombocytopeniaBlood and lymphatic system disorders4/130/130/143/142/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Romiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus DecitabineTotal
Mean67.3 (58 to 86)71.9 (56 to 86)71.4 (61 to 81)70.5 (52 to 84)68.2 (55 to 81)69.8 (52 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus DecitabineTotal
Female6373726
Male710711843
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romiplostim (AMG 531) Placebo Plus AzacitidineRomiplostim (AMG 531) 500 mcg Plus AzacitidineRomiplostim (AMG 531) 750 mcg Plus AzacitidineRomiplostim (AMG 531) Placebo Plus DecitabineRomiplostim (AMG 531) 750 mcg Plus DecitabineTotal
White or Caucasian13101491157
Black or African American020114
Hispanic or Latino000235
Asian010203
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma. 2013 Feb;54(2):321-8. doi: 10.3109/10428194.2012.713477. Epub 2012 Nov 15. PubMed 22906162 ↗
  • Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28;116(17):3163-70. doi: 10.1182/blood-2010-03-274753. Epub 2010 Jul 14. PubMed 20631375 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2006 to primary completion in Oct 2009, 36 months.

Results were first posted in Apr 2011, 1 year 5 months after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 36 months is close to that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2006
First posted
May 4, 2006
StartActual
Oct 1, 2006
Primary completionActual
Oct 19, 2009
CompletionActual
Oct 19, 2009
Results first posted
Apr 5, 2011
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00321711
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 4, 2006
Start date
Oct 1, 2006
Primary completion
Oct 19, 2009
Completion
Oct 19, 2009
Results posted
Apr 5, 2011
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion